Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candi5V vaccine for recurrent vulvovaginal candidiasis
NCT06190509Phase 2Active, not recruiting
- Sponsor
- LimmaTech Biologics
- Start
- Dec 2023
- Primary completion
- Apr 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of Candi5V in recurrent vulvovaginal candidiasis (RVVC), sponsored by LimmaTech Biologics. Started Dec 2023; status: active, not recruiting.
02
Drugs
Candi5V
03
Conditions
recurrent vulvovaginal candidiasis (RVVC)
Beyond the preview
Go deeper on NCT06190509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06190509.